Smith & Nephew leans on debt for Osiris buy

By Mike Turner
12 Mar 2019

UK medical equipment manufacturer Smith & Nephew has agreed to buy US firm Osiris Therapeutics using cash and debt, as consolidation in the healthcare sector continues to provide one of the few bright spots for M&A activity this year.

Smith & Nephew said it would buy regenerative medicine company Osiris for $19 a share in cash, valuing the target company at around $660m and a 37% premium to the 90 day weighted volume of the target’s shares at pre-announcement levels.

The UK firm is paying for the acquisition ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.